€83.07
0.18% yesterday
Paris, Jun 23, 05:35 pm CET
ISIN
FR0000120578
Symbol
SAN
Sector
Industry

Sanofi Stock price

€83.07
-9.07 9.84% 1M
-8.71 9.49% 6M
-10.67 11.38% YTD
-7.29 8.07% 1Y
-9.67 10.43% 5Y
-8.46 9.24% 10Y
+15.15 22.31% 20Y
Paris, Closing price Mon, Jun 23 2025
-0.15 0.18%
ISIN
FR0000120578
Symbol
SAN
Sector
Industry

Key metrics

Market capitalization €101.37b
Enterprise Value €114.42b
P/E (TTM) P/E ratio 10.03
EV/FCF (TTM) EV/FCF 10.47
EV/Sales (TTM) EV/Sales 1.66
P/S ratio (TTM) P/S ratio 1.47
P/B ratio (TTM) P/B ratio 1.41
Dividend yield 4.71%
Last dividend (FY24) €3.92
Revenue (TTM) Revenue €69.05b
EBIT (operating result TTM) EBIT €16.01b
Free Cash Flow (TTM) Free Cash Flow €10.93b
Cash position €7.99b
EPS (TTM) EPS €8.30
P/E forward 12.21
P/S forward 2.22
EV/Sales forward 2.50
Show more

Is Sanofi a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,880 stocks worldwide.

Sanofi Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Sanofi forecast:

20x Buy
77%
6x Hold
23%

Analyst Opinions

26 Analysts have issued a Sanofi forecast:

Buy
77%
Hold
23%

Financial data from Sanofi

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
69,049 69,049
-
100%
- Direct Costs 20,179 20,179
-
29%
48,870 48,870
-
71%
- Selling and Administrative Expenses 14,086 14,086
-
20%
- Research and Development Expense 11,054 11,054
-
16%
18,639 18,639
-
27%
- Depreciation and Amortization 2,627 2,627
-
4%
EBIT (Operating Income) EBIT 16,012 16,012
-
23%
Net Profit 10,247 10,247
-
15%

In millions EUR.

Don't miss a Thing! We will send you all news about Sanofi directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Stock News

AD HOC NEWS
22 days ago
Die Privatbank Berenberg hat das Kursziel für Sanofi FR0000120578 nach Itepekimab- Studiendaten von 120 auf 118 Euro gesenkt, aber die Einstufung auf "Buy" belassen.
AD HOC NEWS
22 days ago
Der Arzneimittelhersteller Sanofi FR0000120578 will mit dem Zukauf des US-Pharmaunternehmens Blueprint Medicines (Blueprint) US09627Y1091 für 9,1 Milliarden US-Dollar (80,2 Mrd Euro) sein Geschäft gegen seltene immunologischen Krankheiten stärken.
AD HOC NEWS
22 days ago
Der Arzneimittelhersteller Sanofi FR0000120578 will mit dem Zukauf des US-Pharmaunternehmens Blueprint Medicines (Blueprint) US09627Y1091 für 9,1 Milliarden US-Dollar (8,0 Mrd Euro) sein Geschäft gegen seltene immunologischen Krankheiten stärken.
More Sanofi News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 82,878
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today